Innoviva (NASDAQ: INVA) — Perfil da empresa, notícias e dados financeiros
Innoviva develops innovative biopharmaceuticals to address unmet medical needs through strategic partnerships and investments.

Innoviva
Innoviva (NASDAQ:INVA) specializes in the development and commercialization of bio-pharmaceuticals, focusing on revolutionary drug options in areas of significant unmet medical need. It stands out for its partnerships aimed at advancing its project pipeline while targeting strategic investments to broaden its portfolio in healthcare and biotechnology sectors. The company strives to improve patient outcomes through innovative medicines, applying rigorous science and research to uncover breakthroughs. Innoviva aims to maintain and expand its presence in the healthcare market, dedicating efforts to both current projects and the exploration of new therapeutic areas to address global health challenges.
Resumo
Operações
Produtos e/ou serviços de Innoviva
- Trelegy Ellipta, a once-daily triple therapy for COPD and asthma management.
- Anoro Ellipta, a bronchodilator duo for improving breathing in COPD patients.
- Relvar/Breo Ellipta, a combination therapy for asthma and COPD treatment.
- Incivo, a medication designed to treat chronic hepatitis C virus.
equipe executiva do Innoviva
- Pavel RaifeldCEO & Director
- Stephen BassoChief Financial Officer
- Marianne ZhenChief Accounting Officer & Secretary
- Patricia M. DrakeChief Commercial Officer-Innoviva Specialty Therapeutics, Inc.
- David AltaracChief Medical Officer of IST
Últimas notícias sobre a Innoviva
Principais indicadores financeiros
Resultados divulgados pela Innoviva, em USD.
- Cap. de mercado
- 1,5 bi
- Receita (TTM)
- 440 mi
- P/L
- 4.9
- LPA (diluído, TTM)
- 4.3
- Dividend yield
- —
- Margem de lucro
- 81.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 425,1 mi | 163,7 mi | 271,2 mi | |
| 358,7 mi | 166,9 mi | 23,4 mi | |
| 310,5 mi | 113,9 mi | 179,7 mi | |
| 331,3 mi | 207 mi | 213,9 mi |